Chembio and Lumira to Develop POC Tests in the ‘Heat’ of COVID-19 Outbreak

Chembio Diagnostics has enlisted LumiraDx to develop point-of-care tests for the detection of the coronavirus (COVID-19). Demand for COVID-19 diagnostics is at a fever-pitch in the US as there is a huge struggle to get the tests into the healthcare system.   Gail Page, Chembio Diagnostics’s interim president and CEO went in more detail about working with Waltham, MA-based LumiraDx during a call with investors. Page said the diagnostics developed in the collaboration would be used on both the LumiraDx and Chembio DPP platforms.   “This expands and strengthens our existing relationship with LumiraDx and further demonstrates our scientific expertise and the versatility of our DPP platform,” Page said, according to a Seeking Alpha transcript of the call. “[Through these] joint efforts we expect the new products to provide comprehensive solutions to the new demand surrounding the worldwide testing needs for COVID-19.”   Page shed more light on the details of the agreement.   “There's a lot more in this agreement that again properly incentivizes and rewards both of us for getting the test to the market in a very expeditious manner,” Page said according to a Seeking Alpha transcript of the call. “… but also, again to point out that we're all very focused taking all the intel...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Business Source Type: news